illumisoft

# Revolutionizing indoor health through *light*

INVESTOR PRESENTATION

TSX-V : UVC    OTCQB : FUVCF

September 2026

LEGAL NOTICE

# Important disclosures.

## FORWARD-LOOKING INFORMATION

This presentation contains "forward-looking information" within the meaning of applicable Canadian securities laws and "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 (collectively, "forward-looking statements"). All statements other than statements of historical fact are forward-looking, including, without limitation, statements regarding product development plans, regulatory pathways, market opportunity, manufacturing capacity, partnership prospects, Far-UVC commercialization timelines, and the company's capital structure.

Forward-looking statements are based on assumptions and estimates management believes reasonable as of the date hereof. Actual results may differ materially due to risks including, but not limited to, regulatory delays, product development risk, competitive pressure, supply-chain disruption, customer adoption rates, capital market conditions, and the risks set forth in the company's continuous disclosure record on SEDAR+. The company undertakes no obligation to update forward-looking statements except as required by law.

## NON-IFRS MEASURES

Certain financial measures referenced herein, including target gross margin, target unit pricing, serviceable addressable market, and bottom-up revenue path, are not recognised under International Financial Reporting Standards. Such measures do not have standardised meanings under IFRS and may not be comparable to similarly titled measures presented by other issuers.

## INDUSTRY AND MARKET DATA

Market data, statistics, and forecasts cited herein are derived from third-party sources, internal estimates, and management assumptions. While the company believes such information to be reliable, it has not been independently verified. Statements regarding market size, penetration rates, competitive positioning, and the performance of competing products reflect management's views and may not be representative of actual outcomes. Independent third-party validation referenced, including the University of Leeds aerobiology study, reflects testing conducted under specified laboratory conditions; real-world performance may vary.

## NO OFFER OR SOLICITATION

This presentation is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any security in any jurisdiction in which such offer or solicitation would be unlawful. Any offer or sale of securities will be made only by means of a prospectus, offering memorandum, or subscription agreement filed or delivered in accordance with applicable securities laws.

## U.S. SECURITIES ACT RESTRICTIONS AND CONFIDENTIALITY

The securities of the company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold within the United States or to U.S. persons (as defined in Regulation S) absent registration or an applicable exemption. This presentation is strictly confidential; reproduction or distribution is prohibited without prior written consent.

illumisoft

# We solved fire. We solved water. We never solved air.

Every other shared risk got permanent infrastructure. Air is still improvised.

### FIRE

Building codes.
Automatic sprinklers.
Smoke alarms.

Solved

### WATER

Municipal treatment.
Sanitation systems.
Safe water on tap.

Solved

### AIRBORNE PATHOGENS

Continuous pathogen reduction built into occupied spaces.

Unsolved

Shared air still has no equivalent layer.

# These are not just buildings. They are where life happens.

### SCHOOLS

Your child
in a classroom.

### SENIOR CARE

Your grandparents
in senior care.

### AVIATION

Your family
on a plane.



### CRUISES

Your next holiday
on a cruise ship.

The ambition: make protection part of the places we already trust.

illumisoft

# People go into hospital to get well.

Around

# 1 in 10

patients is affected by a healthcare-associated infection.

**Protection should not end at the hospital door.**

## 136M

healthcare-associated antibiotic-resistant infections estimated worldwide each year.

**When an infection resists treatment, avoiding it matters even more.**

illumisoft

# The cost does not stop at the bedside.

## US$412B

**Annual treatment expenses**

For resistant bacterial infections.

Modeled to 2035

## US$443B

**Annual productivity losses**

From illness and mortality.

Modeled to 2035

## US$855B

**If nothing changes**

Treatment and productivity, combined.

Modeled to 2035

**Projected worldwide burden up to 2035.**

illumisoft

# A major economic and human cost.

Healthcare-acquired infections are a significant, preventable burden on Canada's healthcare system.

**473,590**

Healthcare-acquired infections a year.

**33,151**

Associated deaths a year.

**C$29.3B**

Estimated annual economic burden.

**C$9.47B** treatment costs
**C$19.85B** lost hospital bed capacity

## Infection prevention is a high-value investment.

Even a modest reduction in infections frees up critical hospital capacity, improves patient outcomes and generates meaningful economic value.

### ILLUSTRATIVE VALUE OF PREVENTED INFECTIONS

At $20,000 per infection avoided. Actual value varies by infection type and setting.

| Infections avoided | 5 | 10 | 25 | 50 |
|---|---|---|---|---|
| Estimated value | $100,000 | $200,000 | $500,000 | $1,000,000 |

1. Fewer infections, lives saved
2. Lower treatment costs
3. More beds and capacity
4. Stronger economic returns

# The money goes to treatment. The leverage is in prevention.

AFTER INFECTION

## Help the patient recover.

Diagnosis. Appropriate treatment. Responsible antibiotic use.

BEFORE EXPOSURE

## Reduce pathogens in shared air.

Add engineered UV to ventilation, filtration and other infection controls.

Illumisoft's role: help make the environment part of prevention.

WHY NOW

# The pressure to act is building.

Standards, procurement, liability and preparedness, 2024 to 2026.

1

## Indoor air is a health crisis

HEALTH CRISIS

Indoor transmission drives the burden, and clean-air expectations have moved.

2

## Standards are tightening

STANDARDS

WHO and CDC raised clean-air targets. ASHRAE 241 sets new clean-airflow rules.

3

## Canada moved first on UV

CANADA FIRST

CSA Z8000:24 adds annexes on supplemental disinfection technologies, and CSA Z317.12:25 addresses UV in healthcare facilities, ahead of global adoption.

4

## Liability drives urgency

PROCUREMENT

Procurement is converting from awareness into signed contracts.

GLOBAL COMPETITIVE POSITION

illumisoft

# Built for global leadership.

## SaniLume

COMMERCIAL UPPER ROOM GUV

ACTIVE

**Best at Leeds**

Best UV device tested in the Leeds chamber.



## SaniLux

FAR-UVC IN DEVELOPMENT

COMING SOON

**70x output**

Against the stated excimer benchmark.

## ECOWing

COMMERCIAL LIGHTING

REVENUE PRODUCING

**34 of 50**

Top DLC products in its category.

$248B+

Market opportunity

20

Granted U.S. patents

99.7%

Chamber pathogen reduction

10+

Verticals served

CONVICTION BEHIND THE MISSION

# Partners in the mission. Invested in its future.

## Chris Anderson

RESILIENCE RESERVE / TED

*"This could greatly enhance social resilience at all levels of global income."*

Helped take TED Talks to a worldwide audience.

## Rob Reid

RESILIENCE RESERVE / RHAPSODY / STRATEGIC ADVISOR

*"Far-UVC is the most promising biosecurity technology I have encountered in two decades of investing at the frontier of science and venture."*

Entrepreneur, technology investor and Illumisoft strategic advisor.

**19.43%**

**Resilience Reserve Ownership**

A PROVEN SCIENTIFIC FOUNDATION

illumisoft

# A century of science. A new level of engineering.

## 1937

### School experiments

Upper-room UV was being studied in classrooms.

## 1994

### CDC guidance

UVGI appeared in healthcare TB-control guidance.

## 2022

### SaniLume testing

The University of Leeds tested Illumisoft's device.

CATEGORY EVIDENCE FOR FAR-UVC, PRINCIPALLY AT 222 NM

| STUDY DESCRIBED | SOURCE-REPORTED FINDING | INTERPRETATION BOUNDARY |
|---|---|---|
| **2020 \| Columbia** | 99.9% inactivation of aerosolized coronaviruses | 222 nm study conditions, not a SaniLux device result |
| **2022 \| Room-sized chamber** | 98.4% reduction in airborne S. aureus, 184 eACH | Experimental room and specified exposure conditions |
| **2023 \| 66-week mouse study** | No increased skin cancer or abnormal growths reported | Animal observations, not proof of long-term human safety |

illumisoft

# Treat the air while the room is in use.

254 nm

UPPER-ROOM GUV

1 **Position**

UV is mounted above head height, so occupants never meet the beam.

2 **Circulate**

Fans draw room air continuously through the germicidal field.

3 **Repeat**

The room keeps operating below while the air above is treated.




CFD aerosol modelling

Pathogens spread through a classroom without the device. The upper-room field treats the air above occupants.

illumisoft

# Best in the Leeds chamber.

**99.7%**

P. aeruginosa reduction
in laboratory chamber testing.

"

*The best performing UV device that has been tested in the aerobiology chamber at the University of Leeds to date.*

**Dr. Louise Fletcher**
University of Leeds / August 2022

| LEEDS CHAMBER ORGANISM | RELEVANCE DESCRIBED IN SOURCE | REDUCTION | EACH |
|---|---|---|---|
| **Pseudomonas aeruginosa** | Antibiotic-resistant / HAI organism | 99.7% | 1,994 |
| **Staphylococcus aureus** | MRSA family, surgical-site pathogen | 99.2% | 744 |
| **Phi-6 bacteriophage** | Enveloped RNA virus, COVID surrogate | 99.1% | 661 |

illumisoft

# A hospital program with meaningful scale.

**1,500**

Budgeted SaniLume units across two hospital programs.

**1,000** — **Winnipeg**
Tertiary facility

**500** — **BC + Fraser Health**
Partnered study

STILL CONDITIONAL

- CHAIR sign-off
- $200k funder deposit
- On-site audit
- Final scope, capped at budget

1. **Signed LOI**
2. **CHAIR sign-off**
3. **$200k funder deposit**
4. **On-site audit**

illumisoft

# A new source. A broader ambition.

# 216 nm

Proprietary nanoengineered Far-UVC.
Core IP owned by Illumisoft.



IN DEVELOPMENT / OWNED IP

**254 nm** **SaniLume, upper-room GUV**

Treat circulating air above occupants. Shipping today.

**216 nm** **SaniLux, Far-UVC in development**

Develop continuous disinfection for occupied spaces.

illumisoft

# Designed to move beyond excimer.

## 70x
**Power output**

Against the stated excimer benchmark.

## 10,000+
**Hours of product life**

Company-stated development target.

## Owned
**Core Far-UVC IP**

No third-party source licensing dependency claimed.

| METRIC | CONVENTIONAL COMPARATOR IN SOURCE | SANILUX CLAIM / TARGET | OPEN ITEM |
|---|---|---|---|
| **Power output** | Milliwatt range | **Watt range, 70x higher** | Output configuration |
| **Kill time** | 60 to 90 minutes per cycle | **Under 1 minute at peak output** | Occupied-space irradiance is lower |
| **Product life** | Approximately 1,000 hours | **10,000+ hours** | Test basis |
| **Unit price** | $1,000 to $5,000+ | **Deck ~$350, site ~$1,000** | Currency and price basis |
| **Roadmap** | n/a | **Deck Q1 2027, site Q3 2027 to Q1 2028** | Management confirmation required |

illumisoft

# From breakthrough science to products built for real life.

illumisoft | Capgemini

Delivered through frog and Synapse, part of Capgemini.

**EUR 22.5B**
**Global revenue**
Full year 2025

**417,600**
**People worldwide**
As at 30 June 2026

**50+**
**Countries**
Global operations

1

## Design for use

Industrial design and product forms for real environments.

2

## Engineer to build

Engineering architecture, supply chain and manufacturing.

3

## Prepare to launch

Prototypes, pilot readiness and launch planning.

***"We believe Illumisoft's far UVC technology represents an important scientific breakthrough."***

Kaethe Henning / Director, Consumer HealthTech Business, Synapse, part of Capgemini

illumisoft

# Blueprint makes the infrastructure case.

"

*Far-UVC represents one of the highest-leverage funding opportunities in airborne disease and pandemic prevention that we are aware of.*

Blueprint Biosecurity / Blueprint for Far-UVC, 2025

**10:1**

ROI cited for ASHRAE 241 clean-air compliance analyses

**30 to 290x**

Benefit-cost ratios cited for Far-UVC in public indoor spaces

illumisoft

# 34 of the top 50. In one portfolio.

167 lm/W of DLC-listed efficiency, engineered and manufactured in Ottawa.
The revenue base and the warm channel into both UV platforms.

REVENUE PRODUCING

| | | | | | |
|---|---|---|---|---|---|
| **167 lm/W** | **60 to 75%** | **5 min** | **50,000 h** | **17** | **40 to 55%** |
| Peak efficacy | Energy savings | Install time | Lifespan | Patents | Gross margin |

EXISTING LIGHTING RELATIONSHIPS

QuadReal

BGO BentallGreenOal $83B AUM

Triovest

illumisoft

# Start where the need is clear. Expand into everyday life.

## $9.7B

**SaniLume**

Hospital serviceable addressable market.

*230K x 12 units. Source cites $96M at 1%.*

## $5.25B

**SaniLux**

Phase 1: hospitals and aviation.

*Phase 2 schools and commercial, $35B+. 30,000 aircraft x 20 units = 600K units.*

## ~$8B

**ECOWing**

North American LED retrofit market.

*Top five players hold about 20%.*

1
$248B
Infection control, 2024

2
$473B
By 2034

3
6.7%
Stated CAGR

4
5 to 30%
UV penetration

5
40 to 49%
N. America share

illumisoft

# From Canadian execution to global scale.

1

ACTIVE

## Canada first

**10 to 15K**

Units/year capacity reported for Ottawa.

2

QUEUED

## International expansion

**50K**

Units/year capacity target for the next phase.

3

SCALE

## SaniLux commercialization

**216 nm**

Own the Far-UVC platform and sell it directly.

THREE WAYS TO TURN ADOPTION INTO REVENUE

**Sell efficient lighting.**

ECOWing commercial product sales.

40 to 55% gross margin reported

**Sell upper-room GUV.**

SaniLume devices and institutional deployments.

Active revenue product line

**Sell Far-UVC direct.**

SaniLux product sales once development completes.

In development, not yet commercial

illumisoft

# Different relationships prove different things.

| | | | | | |
|---|---|---|---|---|---|
| Health Canada<br>REGULATORY | NRC NATIONAL RESEARCH / CAN<br>R&D PARTNER | QuadReal<br>REAL ESTATE | BGO BentallGreenOal $83B AUM<br>REAL ESTATE | Triovest<br>REAL ESTATE | NATIONAL DEFENCE / CANADA<br>FEDERAL |
| QUEENSWAY CARLETON HOSPITAL<br>HOSPITAL PILOT | CSA Group Z317.12:25<br>STANDARDS BODY | DLC DesignLights<br>RANKINGS | BLUEPRINT BIOSECURITY<br>COALITION | Microbix TSX : MBX<br>BOARD CONNECT | IES Award 2023<br>INDUSTRY AWARD |

| CATEGORY | ORGANIZATIONS NAMED IN SOURCE | MEANING RETAINED |
|---|---|---|
| **Regulation / standards** | Health Canada; CSA | Registration and standards references, not an endorsement or universal mandate |
| **R&D / testing** | NRC; University of Leeds | R&D and Workplace 3.0 context; device testing under stated conditions |
| **Commercial relationships** | QuadReal; BGO; Triovest; BGIS | Existing real-estate and lighting relationships, no GUV purchases inferred |
| **Public sector / hospital** | National Defence; Queensway Carleton Hospital | Federal relationship and hospital-pilot references, as labelled in the source |
| **Commercialization** | Capgemini; frog; Synapse | Product design, engineering and manufacturing-readiness work |
| **Category / recognition** | Blueprint; DLC; IES; Microbix | Advocacy; rankings; recognition; board connection, respectively |

LEADERSHIP AND ADOPTION

illumisoft

# Science, commercialization and adoption.

### Ehsan Agahi

CHIEF EXECUTIVE OFFICER

Zephyr Venture Partners. Biotech and life-sciences M&A.

### Dr. Michael Johnson

CHIEF TECHNOLOGY OFFICER

Physics PhD, ASU. Former Motorola semiconductor. Architect of SaniLux.

### Ali Pickett

CHIEF FINANCIAL OFFICER

15+ yrs financial leadership. Managed $8B+ in assets. TSX-V experience.

## BOARD AND ADVISORS

### Brett Nicholds

STRATEGIC ADVISOR

Led Illumisoft from precommercialization to national distribution.

### Cameron Groome

DIRECTOR

CEO Microbix Biosystems (TSX). Advised Global Affairs Canada.

### Ryan Adam

DIRECTOR

Wellington DuPont. Former PMO Western Canada and Natural Resources.

# Great technology must also get adopted.

**Dr. Jonathan Ketcham**

ILLUMISOFT STRATEGIC ADVISOR

## Former White House Chief Healthcare Economist

2025 to 2026

- Distinguished Research Professor, Arizona State University
- Former Principal Economist, Amazon
- Founder, Margin Health
- PhD in Economics, Wharton

HIS ROLE AT ILLUMISOFT

Build the economic case and help navigate procurement, reimbursement and institutional adoption.

*"The power of light to prevent disease is not just a beautiful metaphor, it is cutting-edge science."*

illumisoft

# Small-cap entry. Global infrastructure ambition.

ILLUMISOFT / TRADING TODAY

## ~C$51M

Indicative basic market capitalization
46,173,389 shares x a C$1.11 reference price, early September 2026. The shares are thinly traded and have ranged roughly C$0.47 to C$1.10 since listing, so this moves with the quote.

R-ZERO / HISTORICAL FINANCING

## ~C$735M

Estimated 2023 post-money valuation
US$526.9M at 16 September 2026 FX. US$105M Series C, US$170M+ raised in total.

WHAT EXECUTION MUST DELIVER

1
**Convert the program**
Finalize hospital scope and complete the conditional deployment steps.

2
**Industrialize SaniLux**
Complete product design, engineering and pilot readiness.

3
**Launch, then scale**
Validate the product and progress toward commercial launch.

CAPITAL STRUCTURE

illumisoft

# Capitalization and capital deployment.

## SHARES OUTSTANDING

| | |
|---|---|
| Issued common shares | 46,173,389 |
| Options | 3,540,000 |
| Finder warrants | 425,390 |

FULLY DILUTED

**50,138,779**

Per the fully diluted table in the 21 April 2026 qualifying transaction closing release.

## USE OF PROCEEDS

| | |
|---|---|
| Manufacturing and inventory scale | ~35% |
| Sales and channel expansion, CA and US | ~30% |
| SaniLux R&D and prototype completion | ~20% |
| Working capital and G&A | ~15% |

illumisoft

# Six reasons. Why Illumisoft.

1

## Standards

### Structural demand

CSA Z8000:24 and Z317.12:25 put engineered air disinfection in front of Canadian healthcare planners.

2

## 1,994 eACH

### Validated performance

1,994 equivalent air changes per hour against P. aeruginosa, versus 0.003 to 17.1 for every other device tested.

3

## 70x

### An unpriced option

70x the stated excimer benchmark, IP owned outright, carrying no value in the market capitalization.

4

## C$2.52M

### Mission-aligned backers

Chris Anderson and Rob Reid subscribed through Resilience Reserve in December 2025.

5

## US$855B

### Two existential tailwinds

Modeled annual treatment and productivity losses from resistant infections, to 2035.

6

## 1,500 units

### An anchor already signed

Two CHAIR hospital programs budgeted under a signed LOI, against roughly C$51M.

Safer air.
Better health.
*Better future.*

illumisoft

WEB
illumisoft.com

CONTACT
info@illumisoft.com

REGISTERED
Ottawa, Canada

LISTINGS
TSX-V : UVC | OTCQB : FUVCF